Lv418
581 积分 2021-08-16 加入
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial
9小时前
已完结
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial
1天前
已完结
The Pharmacology of CAR T Cell Therapy for Autoimmune Disease
2天前
已完结
Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa
2天前
已完结
Advances in the treatment of eosinophilic granulomatosis with polyangiitis
2天前
已完结
Navigating evidence-based recommendations for the management of systemic sclerosis
3天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
5天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
5天前
已完结
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
7天前
已完结
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure
7天前
已完结
皖公网安备34019202002308
